Abridge has partnered with the New England Journal of Medicine (NEJM) and JAMA Network to enhance its AI-powered clinical decision support system with peer reviewed medical evidence, enabling clinicians to access trusted insights directly during patient care.
Glimpse:
Announced in April 2026, Abridge entered multi-year partnerships with NEJM Group and the American Medical Association (publisher of JAMA Network) to integrate peer-reviewed research into its AI platform. The system will allow clinicians to retrieve evidence-based insights before, during, and after patient interactions without leaving their workflow, improving both efficiency and clinical decision-making.
Abridge, a leading AI healthcare company focused on clinical conversations and documentation, has expanded its clinical decision support capabilities through new partnerships with the New England Journal of Medicine (NEJM) and the JAMA Network. The collaboration aims to bring high quality, peer-reviewed medical research directly into clinical workflows.
Under the agreement, content from NEJM and JAMA including multiple specialty journals will be integrated into Abridge’s AI system. This allows clinicians to ask medical questions and receive responses grounded in both patient specific context and rigorously validated scientific evidence.
Traditionally, clinicians had to leave their workflow and search external databases to access medical literature. With this integration, Abridge enables real-time, context-aware insights during patient encounters, helping providers make faster and more informed decisions without disrupting care delivery.
The platform supports the full clinical workflow from pre-visit preparation and capturing patient conversations to generating structured documentation and surfacing evidence-based recommendations. This end to end approach enhances both clinical efficiency and care quality.
Abridge’s decision support capabilities already include integrations with tools like Wolters Kluwer’s UpToDate, and the addition of NEJM and JAMA content further strengthens its evidence layer. The new content is expected to roll out more broadly in the coming months.
Currently used across more than 250 health systems in the United States, Abridge’s platform is part of a growing wave of generative AI solutions aimed at reducing clinician workload while improving access to reliable medical knowledge.
The partnership also addresses a key concern in healthcare AI accuracy by ensuring that AI-generated responses are supported by source backed, peer reviewed evidence, allowing clinicians to verify information and maintain trust in decision making.
“There is no higher scientific standard in medicine than the research published in NEJM and JAMA.”
By
HB Team
Related News
